Loading…
Treace Medical Concepts Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in TMCI.
▼ -80.5% over 5Y.
today you would have $167.29▼ -83.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $2.45 | $7.44 | $12.75 | $22.99 | $18.64 | |
| P/S | 4.2x | 0.7x | 2.2x | 4.2x | 9.9x | 10.8x |
| P/B | 5.7x | 1.8x | 4.1x | 5.7x | 23.2x | 11.0x |
| EPS | -$0.93 | -$0.90 | -$0.81 | -$0.77 | -$0.43 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| VNDAVanda Pharmaceuticals Inc. | $5.04 | — | 1.1x | — | -77.81% | $304.73M |
| TTRXTurn Therapeutics Inc. | $9.84 | — | 427.8x | — | -686.28% | $298.82M |
| IMRXImmuneering Corp | $4.61 | — | 1.6x | — | -52.15% | $298.26M |
| IRDOpus Genetics, Inc. | $3.69 |
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Company description provided by Yahoo Finance.
| Profit margin | -26.63% | -27.74% | -26.63% | -26.47% | -30.19% | -21.77% |
| ROE | -49.38% | -67.56% | -49.38% | -35.91% | -70.73% | -22.08% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| -4796.52% |
| $306.99M |
| TLSITriSalus Life Sciences, Inc. | $4.83 | — | 45.1x | — | — | $297.41M |
| CVCapsoVision, Inc | $5.93 | — | 22.5x | — | -335.06% | $296.78M |